Onoact (landiolol) / Ono Pharmaceutical - LARVOL DELTA

Efficacy and safety of Landiolol in cardiogenic shock patients. (PubMed, Chest) - No abstract available

Journal • Cardiovascular

What If We Let It Fibrillate? New Perspective on Atrial Fibrillation in Sepsis. (PubMed, Curr Med Sci) - "Studies with ultrashort-acting beta-blockers, such as esmolol and landiolol, have shown that hemodynamic stabilization may occur even in the absence of sinus rhythm restoration. Recognizing AF as a potential adaptive rhythm reframes research priorities: identifying biomarkers of atrial inflammation, stratifying patients according to hemodynamic impact, and testing permissive versus corrective strategies in prospective trials. The permissive AF strategy proposed herein is expected to foster patient-centered care and reduce iatrogenic harm in the complex interplay between sepsis and the heart."

Journal • Atrial Fibrillation • Cardiovascular • Critical care • Infectious Disease • Inflammation • Septic Shock

Cardiovascular Effects of Landiolol in Intensive Care Patients: A Retrospective Safety Analysis (SCCM 2026) - "In our experience, landiolol appears to be a safe option for treating supraventricular tachyarrhythmia in ICU patients. Careful dose titration to target HR, as recommended by atrial fibrillation guidelines, can be achieved with relatively low doses of landiolol, with minimal impact on blood pressure and stable vasopressor requirements over time."

Retrospective data • Atrial Fibrillation • Cardiovascular • Critical care • Septic Shock • Ventricular Tachycardia

Learn about the latest treatment for Supraventricular Tachycardia (SCCM 2026) - "Organized by AOP Healthcare. This presentation will discuss a treatment option for IV rate control and the recent approval for landiolol in the U.S. Learn how this treatment may be an option for your institution."

Cardiovascular • Ventricular Tachycardia

The effect of early Landiolol in patients with ST-elevation acute coronary syndrome undergoing primary percutaneous coronary intervention A prospective, randomized, double-blinded, placebo-controlled, phase IV pilot trial (STEMILAND-1) (clinicaltrialsregister.eu) - P4 | N=60 | Not yet recruiting | Sponsor: Medical University Of Vienna

New P4 trial • Acute Coronary Syndrome • Cardiovascular

Landiolol for rate control in decompensated heart failure due to atrial fibrillation - the LARISA trial. (PubMed, Eur Heart J Acute Cardiovasc Care) - "In AHF with reduced LVEF, protocolized landiolol-based intensive rate control provides faster and safe HR reduction with early symptomatic benefit compared with standard therapy."

Journal • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypotension • Pulmonary Disease

Effects of Dual Orexin Receptor Antagonists on Seizure Quality in Modified Electroconvulsive Therapy: A Pilot Study. (PubMed, J ECT) - "DORA use during m-ECT did not impair seizure quality, supporting their safe concomitant use. Findings were consistent across subgroup, agent, and dose-response analyses. Larger prospective trials are warranted to confirm these results."

Journal • CNS Disorders • Epilepsy • Insomnia • Sleep Disorder

A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III clinical trial of landiolol hydrochloride for injection in the treatment of patients with tachycardia arrhythmia during surgery under general anesthesia was conducted (ChiCTR) - P3 | N=210 | Not yet recruiting | Sponsor: The Third Xiangya Hospital of Central South University; The Third Xiangya Hospital of Central South University

New P3 trial • Anesthesia • Cardiovascular

Comparison of Efficacy and Safety Between Landiolol and Esmolol in Critically Ill Patients with Tachycardia (ChiCTR) - P=N/A | N=120 | Not yet recruiting | Sponsor: The First Affiliated Hospital with Nanjing Medical University; The First Affiliated Hospital with Nanjing Medical University

New trial • Cardiovascular

Research progress on beta-blockers in the treatment of sepsis-induced cardiomyopathy: A mini review. (PubMed, SAGE Open Med) - "Short-acting β₁-blockers (esmolol, landiolol) offer a targeted therapeutic approach by reducing heart rate (target: 80-95 bpm), myocardial oxygen demand, and proinflammatory cytokines while improving diastolic perfusion-leveraging ultra-short half-lives (t₁/₂ = 4-9 min) for rapid reversibility during instability. Current limitations include heterogeneous trial designs, small samples, and undefined benefiting phenotypes. Thus, cautious short-acting β-blockade is supported only for selected SCM patients with hemodynamic stability (MAP ⩾65 mmHg, normalized lactate, LVEF >35%), necessitating future precision trials with AI phenotyping to guide mechanism-targeted application."

Journal • Review • Cardiomyopathy • Cardiovascular • Heart Failure • Infectious Disease • Inflammation • Septic Shock

Landiolol in patients with supraventricular arrhythmias: real-world efficacy and safety. (PubMed, Eur Heart J Acute Cardiovasc Care) - No abstract available

Journal • Real-world evidence • Atrial Fibrillation • Cardiovascular

Budget Impact Analysis of Landiolol, an Ultra-short-acting Beta-antagonist, for the Treatment of Sepsis/SIRS-related Supraventricular Tachycardia in the ICU: US Perspective (ASHP 2025) - No abstract available

HEOR • Cardiovascular • Infectious Disease • Septic Shock • Ventricular Tachycardia

Cost-Effectiveness Analysis of Landiolol, an Ultra-short-acting Beta-antagonist, for Treatment of Sepsis/SIRS-related Supraventricular Tachycardia in the ICU: US Perspective (ASHP 2025) - No abstract available

Cost effectiveness • HEOR • Cardiovascular • Infectious Disease • Septic Shock • Ventricular Tachycardia

Cost-Effectiveness Analysis of Landiolol, an Ultra-short-acting Beta-antagonist, for Treatment of Sepsis/SIRS-related Supraventricular Tachycardia in the ICU: US Perspective (ASHP 2025) - "Hosted by the Section of Clinical Specialists and Scientists"

Cost effectiveness • HEOR • Cardiovascular • Infectious Disease • Septic Shock • Ventricular Tachycardia

Comparison of Esmolol Versus Landiolol on Mortality in Adult Patients With Sepsis: A Systematic Review and Network Meta-Analysis. (PubMed, Crit Care Med) - "Among patients with sepsis treated with β-blockers, esmolol probably improves clinical outcomes compared with SOC. However, the effect of landiolol remains uncertain due to the low certainty of evidence. Esmolol may confer a relative clinical advantage over landiolol, but further studies are needed to confirm this finding and elucidate the underlying mechanisms."

Journal • Retrospective data • Infectious Disease • Septic Shock

The controversies in the clinical management of β-blockers in acute heart failure induced by rapid atrial fibrillation: A narrative review. (PubMed, Am Heart J Plus) - "AF management guidelines generally recommend considering the addition of β-blockers when digoxin-like drugs (such as cedilanid) fail to effectively control the ventricular rate...This article systematically reviews the clinical management strategies under this guideline contradiction, including: (1) Different recommendations on ventricular rate control and the use of β-blockers in domestic and international guidelines for AF and HF; (2) A pooled analysis of relevant research evidence; (3) Application strategies of β-blockers (especially short-acting agents esmolol and landiolol) in the acute phase...Although some studies and consensus articles have focused on the management of rapid AF complicated by HF, there is currently a lack of systematic reviews on this issue. Therefore, the writing of this review has important academic value and clinical guiding significance, providing a reference for treatment decisions in this special population."

Journal • Review • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure

Low dose of landiolol does not prevent postoperative atrial fibrillation after cardiac surgery in non-Asian patients: a multicentre randomised study. (PubMed, Br J Anaesth) - P3 | "In non-Asian patients undergoing cardiac surgery with CPB, a low-dose 24-h infusion of landiolol, used as a bridge to oral beta-blockers, did not reduce the incidence of postoperative atrial fibrillation."

Journal • Atrial Fibrillation • Cardiovascular • Critical care

A Case Report of Thyroid Storm with Cardiovascular Collapse After Propranolol Administration. (PubMed, Clin Pract Cases Emerg Med) - "Beta-blocker use in the management of thyrotoxicosis can potentially cause cardiovascular collapse. We suggest consideration of shorter acting beta blockers, such as esmolol or landiolol."

Journal • Cardiomyopathy • Cardiovascular • Critical care • Gastroenterology • Gastrointestinal Disorder • Grave’s Disease • Infectious Disease • Myocardial Infarction

The art of conducting a good pilot study: a discussion of the BETA-ARREST pilot trial. (PubMed, Resusc Plus) - "In this paper, we provide a critical appraisal of the BETA-ARREST trial "Landiolol for Refractory Ventricular Fibrillation in Out-of-hospital Cardiac Arrest: a Randomized, Double-blind, Placebo-controlled, Pilot Trial" by Gelbenegger et al. 2024, and discuss what constitutes a good pilot study."

Clinical • Journal • Cardiovascular

Clinical effect of dexmedetomidine combined with landiolol hydrochloride on cerebral oxygen metabolism and inflammatory response in patients with severe craniocerebral injury. (PubMed, BMC Anesthesiol) - No abstract available

Journal • Inflammation

Protective impact of landiolol against acute lung injury following hemorrhagic shock and resuscitation in rats. (PubMed, Mol Med Rep) - "In conclusion, landiolol administration after HSR reduced lung inflammation and apoptosis, suggesting a potential improvement in tissue damage. Furthermore, pAMPKα activation in the HSR/landiolol group may be the mechanism underlying the pulmonary protective effects of landiolol."

Journal • Preclinical • Acute Lung Injury • Hematological Disorders • Hypotension • Inflammation • Oncology • Pneumonia • Respiratory Diseases • CASP3 • TNFA

CARDIOVASCULAR EFFECTS OF LANDIOLOL IN INTENSIVE CARE PATIENTS: A RETROSPECTIVE SAFETY ANALYSIS (CHEST 2025) - "In our experience, landiolol appears to be a safe option for treating supraventricular tachyarrhythmia in ICU patients. Careful dose titration to target HR, as recommended by atrial fibrillation guidelines, can be achieved with relatively low doses of landiolol, with minimal impact on blood pressure and stable vasopressor requirements over time. CLINICAL IMPLICATIONS: Landiolol appears to be a safe option for treating supraventricular tachyarrhythmia in ICU patients."

Retrospective data • Atrial Fibrillation • Cardiovascular • Critical care • Septic Shock • Ventricular Tachycardia

COMPARATIVE EFFECTIVENESS OF BETA BLOCKERS ON MORTALITY AND CLINICAL OUTCOMES IN ADULTS WITH SEPTIC SHOCK: A COMPREHENSIVE SYSTEMATIC REVIEW AND BAYESIAN NETWORK META-ANALYSIS (CHEST 2025) - "Esmolol appears to be the most effective beta blocker for reducing mortality and improving clinical outcomes in septic shock. It showed significant reductions in 28-day mortality, ICU mortality, heart rate, and serum lactate levels, as well as a shorter ICU stay. In comparison, landiolol demonstrated less effectiveness."

Clinical data • HEOR • Retrospective data • Review • Metabolic Disorders • Septic Shock

Differential Mortality Benefit of Beta-blockers in Septic Shock: A Subgroup Meta-analysis. (PubMed, Indian J Crit Care Med) - "Esmolol appears beneficial, while Ivabradine and Landiolol show no clear mortality advantage. Differential Mortality Benefit of Beta-blockers in Septic Shock: A Subgroup Meta-analysis. Indian J Crit Care Med 2025;29(8):704-707."

Journal • Retrospective data • Cardiovascular • Septic Shock

Prevention and Treatment of New-Onset Postoperative Atrial Fibrillation in the Acute Care Setting: A Narrative Review. (PubMed, J Clin Med) - "Considering on the one hand its serious adverse effects and complex drug interactions, and on the other hand discrepancies among recent international guidelines, the indications of amiodarone to both prevent and treat POAF should be reserved to patients at high risk of POAF only, or patients with hemodynamic instability and/or severely reduced left ventricular ejection fraction. Given their efficient and safe profile, ultra-short-acting intravenous beta-blockers like esmolol or landiolol could be preferentially used in acute care patients. Besides waiting for the results of ongoing RCTs in cardiac and noncardiac surgery, the use of oral anticoagulation in patients with POAF should take into account the individualized thromboembolic/hemorrhagic risk ratio."

Journal • Review • Atrial Fibrillation • Cardiovascular • Hematological Disorders